Vilacto Bio Announces Launch of Carmen Electra by Vilact®
Press Release | 10/01/2018
COPENHAGEN, Denmark, Oct. 01, 2018 (GLOBE NEWSWIRE) — Vilacto Bio Inc. (OTC QB:VIBI) has launched its new skincare product, Carmen Electra by Vilact, based on the company’s LACTOACTIVE® compound.

LACTOACTIVE® is the first variant of a patented particle the company has used to produce a range of popular skincare products. Customers have given Carmen Electra by Vilact rave reviews, and the new product won the “Buyers’ Choice” award at a ECRM event held in Las Vegas in June.

“Thanks to the fantastic response from customers and buyers, Carmen Electra by Vilact has given us a valuable opportunity to spread the word about Vilact products and our LACTOACTIVE® compound,” says Vilacto Bio CEO Gert Anderson.

In addition to using the LACTOACTIVE® compound in its skin creams – now spun off as a separate business unit – Vilacto Bio is moving into biotech with its new LACTOACTIVE iTHER® compound. In the long run, Vilacto Bio expects LACTOACTIVE iTHER® to help develop further and even more powerful skincare solutions, along with therapeutic treatments for a range of medical conditions.

About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented LACTOACTIVE® (Lactoactive particle), has demonstrated in numerous studies above-average efficacy in treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and other skin ailments. The company aims to further develop its particles for the purpose of increasing the quality of our retail and medical skin cream products, as well as licensing for use in the pharmaceutical industry.

Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain “forward-looking” statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Vilacto Bio Inc.
Fabriksvej 48
4700 Næstved
Denmark

Gert Andersen
Phone: +1 646-893-7895
info@vilactobio.com
www.vilactobio.com